Log In
BCIQ
Print this Print this
 

44PXN4017

  Manage Alerts
Collapse Summary General Information
Company Priaxon AG
DescriptionMDM2/p53 Inhibitor
Molecular Target Mdm2 p53 binding protein homolog (MDM2) (HDM2)
Mechanism of ActionMdm2 p53 binding protein homolog (MDM2) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL)
Regulatory Designation
PartnerBoehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today